.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Boehringer Ingelheim
Dow
McKesson
Daiichi Sankyo
Argus Health
Colorcon
Chubb
Chinese Patent Office
Merck

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,455,533

« Back to Dashboard

Which drugs does patent 6,455,533 protect, and when does it expire?


Patent 6,455,533 protects CHILDREN'S ZYRTEC ALLERGY and CHILDREN'S ZYRTEC HIVES RELIEF and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.

Summary for Patent: 6,455,533

Title: Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
Abstract:The invention concerns pharmaceutical compositions for oral administration, comprising an active substance belonging to the family of substituted benzhydrylpiperazines and at least a cyclodextrin.
Inventor(s): Fanara; Domenico (Wanze, BE), Berwaer; Monique (Ham-sur-Heure-Nalinnes, BE), Nolf; Philippe (Brussels, BE), Vranckx; Henri (Brussels, BE), Deleers; Michel (Linkebeek, BE)
Assignee: UCB, S.A. (Brussels, BE)
Application Number:09/446,735
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
J And J Consumer IncCHILDREN'S ZYRTEC ALLERGYcetirizine hydrochlorideTABLET, CHEWABLE;ORAL021621-003Nov 16, 2007DISCNYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
J And J Consumer IncCHILDREN'S ZYRTEC ALLERGYcetirizine hydrochlorideTABLET, CHEWABLE;ORAL021621-004Nov 16, 2007DISCNYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
J And J Consumer IncCHILDREN'S ZYRTEC HIVES RELIEFcetirizine hydrochlorideTABLET, CHEWABLE;ORAL021621-005Nov 16, 2007DISCNYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
J And J Consumer IncCHILDREN'S ZYRTEC HIVES RELIEFcetirizine hydrochlorideTABLET, CHEWABLE;ORAL021621-006Nov 16, 2007DISCNYesNo► Subscribe► Subscribe► SubscribeYTREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,455,533

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Belgium9700572Jul 03, 1997
PCT Information
PCT FiledJuly 02, 1998PCT Application Number:PCT/BE98/00100
PCT Publication Date:January 14, 1999PCT Publication Number: WO99/01133

International Patent Family for Patent: 6,455,533

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria224717► Subscribe
Australia727140► Subscribe
Australia8201598► Subscribe
Belgium1011251► Subscribe
Brazil9810495► Subscribe
Canada2294783► Subscribe
China1150900► Subscribe
China1261799► Subscribe
Germany69808297► Subscribe
Denmark0994710► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Dow
Merck
US Department of Justice
Colorcon
Covington
Farmers Insurance
Boehringer Ingelheim
Deloitte
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot